Key Points Interested in Moderna, Inc.? Here are five stocks we like better. Moderna shares rose nearly 20% after Science Day ...

The company's pending vaccine approvals could help the stock continue its rise.

Moderna remains a Sell as regulatory setbacks, notably the FDA's Refusal-to-File for mRNA-1010, highlight persistent execution and approval risks. The RTF for mRNA-1010 delays potential influenza ...

The recent downturn follows Moderna’s announcement that its melanoma vaccine, mRNA-4157, showed promising results in a Phase 2b study, reducing the risk of recurrence or death by 49% when combined ...

Cancer was a key focus, with programs targeting solid tumors, Lynch syndrome, melanoma, and non-small cell lung cancer.

Moderna currently has three marketed products in its portfolio — two COVID-19 vaccines (Spikevax and mNexspike) and an RSV vaccine (mResvia). The Zacks Consensus Estimate for overall product sales is ...

Moderna Inc. (NASDAQ:MRNA) is one of the best performing S&P 500 stocks so far in 2026. On April 21, the European Commission granted marketing authorization for mCOMBRIAX (mRNA-1083), making it the ...

Moderna announced Thursday it will receive up to $54.3 million from a global vaccine partnership to fund its ongoing research into a potential bird flu mRNA vaccine, helping to recover some of the ...